Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer

Annals of Surgical Oncology

Volumn 13, Issue 8, 2006, Pages 1078-1084

  Kimata, Hideto ^a   Imai, Tsuneo ^a   Kikumori, Toyone ^a   Teshigahara, Osamu ^a   Nagasaka, Tetsuro ^a   Goshima, Fumi ^a   Nishiyama, Yukihiro ^a   Nakao, Akimasa ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Breast cancer; Cancer; Clinical study; Herpes virus therapy; Oncolytic viral therapy; UL56

Indexed keywords

ALPHA1 INTERFERON; ANASTROZOLE; ANTINEOPLASTIC AGENT; BETA INTERFERON; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; HERPES SIMPLEX VACCINE; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 12; MEDROXYPROGESTERONE ACETATE; METHOTREXATE; ONCOLYTIC VIRUS; PACLITAXEL; TRASTUZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; PILOT STUDY; SKIN METASTASIS; TUMOR VOLUME; VIRUS MUTANT; VIRUS STRAIN;

AGED; ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOLYTIC VIROTHERAPY; PILOT PROJECTS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 33748336673     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/ASO.2006.08.035     Document Type: Article

References (17)

1. Nishiyama Y, Kimura H, Daikoku T. Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus type 1 and 2. J Virol 1990; 65:4520-4.
2. Yamada Y, Kimura H, Morishima T, Daikoku T, Maeno K, Nishiyama Y. The pathogenicity of ribonucleotide reductase-null mutants of herpes simplex virus type 1 in mice. J Infect Dis 1991; 164:1091-7.
3. Nishiyama Y, Yamada Y, Kurachi R, Daikoku T. Construction of a US3 lacZ insertion mutant of herpes simplex virus type 2 and characterization of its phenotype in vitro and in vivo. Virology 1992; 190:256-68.
4. Takakuwa H, Goshima F, Nozawa N, et al. Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice. Arch Virol 2003; 148:813-25.
5. Kimata H, Takakuwa H, Goshima F, et al. Effective treatment of disseminated peritoneal colon cancer with new replication-competent herpes simplex viruses. Hepatogastroenterology 2003; 50:961-6.
6. Teshigahara O, Goshima F, Takao K, et al. Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF10. J Surg Oncol 2004; 85:42-7.
7. Becker Y, Hadar J, Tabor E, et al. A sequence in Hpal-P fragment of herpes simplex virus-1 DNA determines intraperitoneal virulence in mice. Virology 1986; 149:255-9.
8. Berkowitz C, Moyal M, Rösen-Wolff A, Darai G, Becker Y. Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice. Arch Virol 1994; 134:73-83.
9. Koshizuka T, Goshima F, Takakuwa H, et al. Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J Virol 2002; 76:6718-28.
10. Committee for Production of Histopathological Criteria, Japanese Breast Cancer Society. Histopathological criteria for assessment of therapeutic response in breast cancer. Breast Cancer 2001; 8:1-7.
11. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese RM. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256:1550-2.
12. Qazilbash MH, Xiao X, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther 1997; 4:675-82.
13. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252:854-6.
14. Goldstein DJ, Weller SK. Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: characterization of an ICP6 deletion mutant. Virology 1988; 166:41-51.
15. Wong RJ, Kim SH, Joe JK, Shah JP, Johnson PA, Fong YM. Effective treatment of head and neck squamous cell carcinoma by an oncolytic herpes simplex virus. J Am Coll Surg 2001; 193:12-21.
16. Cozzi PJ, Malhotra S, McAuliffe P, et al. Intravesical oncolytic viral therapy using attenuated, replication-competent herpes simplex viruses G207 and Nv1020 is effective in the treatment of bladder cancer in an orthotopic syngeneic model. FASEB J 2001; 15:1306-8.
17. Meignier B, Martin B, Whitley RJ, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (Aotus trivirgatus). J Infect Dis 1990; 162:313-21.